| Status | Awaiting development |
| Technology type | Medicine |
| Decision | None selected |
| Process | STA Standard |
| ID number | 3944 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 25 March 2025 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late September 2026. |
| 13 January 2025 | As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Durvalumab with bevacizumab and transarterial chemoembolisation within its marketing authorisation for treating locally advanced hepatocellular carcinoma [ID3944]. Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early January 2026 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early March 2026. |
| 29 November 2024 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early July 2025 when we will write to you about how you can get involved. |
| 17 October 2024 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early January 2026 when we will write to you about how you can get involved. |
| 21 June 2024 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early April 2026 when we will write to you about how you can get involved. |
| 20 June 2023 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early October 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early December 2024. |
For further information on our processes and methods, please see our CHTE processes and methods manual